Federal research funding is a distinct part of the financing landscape for technology companies. Understanding its purpose, administration and award levels helps founders compare research awards with equity capital and describe each source clearly in a business plan.
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are known together as America's Seed Fund. They award non-dilutive funding to develop technology and chart a path toward commercialization, meaning the route from a technical idea to a marketable product or service.
Non-dilutive funding means that receiving the funding does not itself require selling an ownership share in the company. This makes the ownership question different from an equity round, where investment is exchanged for a stake in the business. The distinction concerns the form of capital; it does not establish whether a particular project will receive an award.
The Small Business Administration reports that, since 1982, the two programs have invested more than $81 billion in over 34,000 small businesses. Those figures describe the programs' combined history, rather than the funding available to an individual company or a prediction of future awards.
According to the federal SBIR/STTR program overview, the Small Business Administration coordinates America's Seed Fund, while 11 participating federal agencies provide funding. Each agency administers its own SBIR/STTR program within guidelines established by Congress. Coordination and administration are therefore separate roles.
For planning purposes, it helps to identify the agency and program behind a possible research award rather than treating federal research funding as a single, interchangeable source of cash. An agency's own program details matter when considering how a project fits. A general program overview provides context, but does not settle the particulars of an individual funding opportunity.
A comparison can start with the technology being developed, the work proposed and the intended commercial use. Keeping those points together makes it easier to explain why research funding belongs in the plan and which business needs would still require another source of capital.
The federal overview states that, as of April 2026, an agency may issue a Phase I award of up to $323,090 or a Phase II award of up to $2,153,927 without seeking Small Business Administration approval. These amounts include modifications to an award. Awards above those levels require a waiver.
The figures are thresholds for awards without that additional approval, rather than promised payments. A budget can keep the stated threshold separate from the amount a project actually needs and any funding that has been confirmed. That distinction avoids treating the largest permitted amount as the expected amount.
When comparing funding options, a clear worksheet can place the proposed research budget beside the award amount being considered, identify any remaining gap and show how that gap affects the broader company plan. This is a budgeting exercise, not a prediction that an award will be made.
The House Committee on Small Business's March 17, 2026 release states that SBIR and STTR authority expired on September 30, 2025, and that the House passed S. 3971 on March 17, 2026. The Small Business Administration subsequently reported that the Small Business Innovation and Economic Security Act was signed into law on April 13, 2026, reauthorizing both programs through September 30, 2031.
The sequence matters when interpreting a funding reference: expiration, passage in the House and enactment are separate events. A statement about the lapse describes a different point in time from a statement about the enacted authorization. The authorization period also answers a different question from whether a particular company has secured funding for its proposed work.
A financing plan can consider research awards and equity capital together while describing their purposes separately. For example, the plan can set out the technical work under consideration, the commercial steps that follow it and the money associated with each. This keeps a research objective visible within the larger business strategy.
Ownership is one part of that comparison. Timing, the amount under consideration and the work the money is intended to support also belong in the discussion. A smaller amount tied to a defined research task may answer a different planning question from capital intended for broader commercial expansion.
It is useful to distinguish a financing possibility from a completed financing. A cash forecast can show confirmed funds in one scenario and a possible award in another. The comparison then reveals which milestones depend on uncertain funding, without assuming that non-dilutive capital will remove every financing need or determine a future equity valuation.
A concise funding worksheet can organize the main questions before a research award is included in a financial forecast:
These questions connect the funding discussion to the work itself. They also make room for an alternative scenario if an award is smaller than anticipated or does not arrive. Clear assumptions allow readers to understand both the proposed research and the remaining capital needs without confusing program-wide figures with company-specific commitments.